A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetic Profile of OROS Hydromorphone in Healthy Adult Taiwanese Subjects Having Different Genotypes for the UGT2B7 Gene

NCT01487564 Phase 1 COMPLETED

The purpose of this study is to investigate the pharmacokinetics of OROS hydromorphone in healthy adult Taiwanese participants after the oral administration of a single 16 mg dose.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	COMPLETED
Enrolment	29
Start date	2011-10
Completion	2012-01

Conditions

• Healthy Volunteers

Interventions

• Hydromorphone 16 mg

Primary outcomes

• Plasma hydromorphone concentration — 20 time points up to 72 hours post-dose

Countries

Taiwan